Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)

This publication has 16 references indexed in Scilit:

• Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study
  Leukemia & Lymphoma, 2004
• Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation
  Biochemical Pharmacology, 2003
• High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas
  Zeitschrift für Krebsforschung und Klinische Onkologie, 2002
• Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkinʼs lymphomas
  Anti-Cancer Drugs, 2001
• Current approaches to the management of non-Hodgkin's lymphoma.
  1998
• Non-Hodgkin-Lymphome
  Die Innere Medizin, 1997
• Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines
  Anti-Cancer Drugs, 1996
• A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
  1994
• Reporting outcomes in Hodgkin's disease and lymphoma.
  1987
• Advanced Lymphosarcoma: Intensive Cyclical Combination Chemotherapy with Cyclophosphamide, Vincristine, and Prednisone
  Annals of Internal Medicine, 1972